A Phase I/II Study of the Raf Kinase/VEGFR Inhibitor Sorafenib in Combination With the mTOR Inhibitor RAD001 (Everolimus) in Patients With Relapsed Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Multiple Myeloma.

Trial Profile

A Phase I/II Study of the Raf Kinase/VEGFR Inhibitor Sorafenib in Combination With the mTOR Inhibitor RAD001 (Everolimus) in Patients With Relapsed Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Multiple Myeloma.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Feb 2017

At a glance

  • Drugs Everolimus (Primary) ; Sorafenib (Primary)
  • Indications Hodgkin's disease; Multiple myeloma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 20 Dec 2016 Planned End Date changed from 1 Oct 2016 to 1 Oct 2017.
    • 26 May 2016 Planned End Date changed from 1 Dec 2011 to 1 Oct 2016.
    • 07 Feb 2013 New source identified and integrated (Mayo Clinic, 07-000710).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top